IN2014DN00078A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN00078A IN2014DN00078A IN78DEN2014A IN2014DN00078A IN 2014DN00078 A IN2014DN00078 A IN 2014DN00078A IN 78DEN2014 A IN78DEN2014 A IN 78DEN2014A IN 2014DN00078 A IN2014DN00078 A IN 2014DN00078A
- Authority
- IN
- India
- Prior art keywords
- composition
- oligodeoxynucleotide
- cpg
- allergies
- adjuvants
- Prior art date
Links
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 abstract 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000030852 Parasitic disease Diseases 0.000 abstract 1
- 208000010362 Protozoan Infections Diseases 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 1
- 230000002538 fungal effect Effects 0.000 abstract 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 abstract 1
- 230000003071 parasitic effect Effects 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11305959A EP2548571A1 (en) | 2011-07-22 | 2011-07-22 | Compositions having means for targeting at least one antigen to dendritic cells |
| PCT/EP2012/064425 WO2013014128A1 (en) | 2011-07-22 | 2012-07-23 | Compositions having means for targeting at least one antigen to dendritic cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN00078A true IN2014DN00078A (enExample) | 2015-05-15 |
Family
ID=46548478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN78DEN2014 IN2014DN00078A (enExample) | 2011-07-22 | 2012-07-23 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20140199379A1 (enExample) |
| EP (2) | EP2548571A1 (enExample) |
| JP (1) | JP2014523918A (enExample) |
| CN (1) | CN103796674A (enExample) |
| AU (1) | AU2012288949B2 (enExample) |
| CA (1) | CA2841036A1 (enExample) |
| IL (1) | IL230525A0 (enExample) |
| IN (1) | IN2014DN00078A (enExample) |
| WO (1) | WO2013014128A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2953287A1 (en) * | 2013-06-19 | 2014-12-24 | Massachusetts Institute Of Technology | In vivo targeting of cells with ligand-conjugated particles |
| WO2015013673A1 (en) | 2013-07-25 | 2015-01-29 | Aurasense Therapeutics, Llc | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
| AU2015269412B2 (en) | 2014-06-04 | 2020-03-12 | Exicure Operating Company | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| CN104277094A (zh) * | 2014-07-04 | 2015-01-14 | 文康医疗技术（深圳）有限公司 | Dc靶向肽及其应用 |
| US11213593B2 (en) | 2014-11-21 | 2022-01-04 | Northwestern University | Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| CA2986687A1 (en) * | 2015-05-22 | 2016-12-01 | Brian J. Czerniecki | Manufacturing multi-dose injection ready dendritic cell vaccines |
| WO2016199904A1 (ja) * | 2015-06-10 | 2016-12-15 | 国立大学法人東京大学 | ワクチン用アジュバント、ワクチン、及び免疫誘導方法 |
| US20190010236A1 (en) * | 2015-12-29 | 2019-01-10 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for dectin-2 stimulation and cancer immunotherapy |
| WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
| US11491114B2 (en) * | 2016-10-12 | 2022-11-08 | Curioralrx, Llc | Formulations for enteric delivery of therapeutic agents |
| WO2018201090A1 (en) | 2017-04-28 | 2018-11-01 | Exicure, Inc. | Synthesis of spherical nucleic acids using lipophilic moieties |
| WO2018203833A1 (en) * | 2017-05-03 | 2018-11-08 | Agency For Science, Technology And Research | Methods for the stimulation of dendritic cell (dc) precursor population "pre-dc" and their uses thereof |
| WO2020245321A1 (en) * | 2019-06-04 | 2020-12-10 | Institut Curie | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF |
| WO2023070317A1 (zh) * | 2021-10-26 | 2023-05-04 | 江苏省农业科学院 | 基于dc细胞的双功能纳米抗体及其构建方法和应用 |
| CN115724992A (zh) * | 2022-07-25 | 2023-03-03 | 江南大学 | 一种志贺毒素b亚基与抗原偶联物及其制备方法与应用 |
| GB202411940D0 (en) * | 2024-08-13 | 2024-09-25 | Univ Exeter | Anti-CLEC12A Antibodies |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2766193B1 (fr) | 1997-07-18 | 2001-09-14 | Inst Curie | Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique |
| EP1229045A1 (en) | 2001-02-01 | 2002-08-07 | Institut Curie | Universal carrier for targeting molecules to Gb3 receptor expressing cells |
| GB0524409D0 (en) | 2005-11-30 | 2006-01-11 | Glaxosmithkline Biolog Sa | Vaccines |
-
2011
- 2011-07-22 EP EP11305959A patent/EP2548571A1/en not_active Ceased
-
2012
- 2012-07-23 IN IN78DEN2014 patent/IN2014DN00078A/en unknown
- 2012-07-23 US US14/234,034 patent/US20140199379A1/en not_active Abandoned
- 2012-07-23 JP JP2014522052A patent/JP2014523918A/ja active Pending
- 2012-07-23 AU AU2012288949A patent/AU2012288949B2/en not_active Ceased
- 2012-07-23 WO PCT/EP2012/064425 patent/WO2013014128A1/en not_active Ceased
- 2012-07-23 CN CN201280036278.3A patent/CN103796674A/zh active Pending
- 2012-07-23 CA CA2841036A patent/CA2841036A1/en not_active Abandoned
- 2012-07-23 EP EP12737819.8A patent/EP2734225A1/en not_active Withdrawn
-
2014
- 2014-01-19 IL IL230525A patent/IL230525A0/en unknown
-
2016
- 2016-07-29 US US15/223,323 patent/US20170042994A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2841036A1 (en) | 2013-01-31 |
| CN103796674A (zh) | 2014-05-14 |
| AU2012288949A1 (en) | 2013-04-11 |
| AU2012288949B2 (en) | 2014-05-01 |
| EP2734225A1 (en) | 2014-05-28 |
| US20140199379A1 (en) | 2014-07-17 |
| US20170042994A1 (en) | 2017-02-16 |
| JP2014523918A (ja) | 2014-09-18 |
| EP2548571A1 (en) | 2013-01-23 |
| WO2013014128A1 (en) | 2013-01-31 |
| IL230525A0 (en) | 2014-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN00078A (enExample) | ||
| EP3698631A3 (en) | Methods of delivering oligonucleotides to immune cells | |
| ZA201301013B (en) | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells | |
| IN2014CN04251A (enExample) | ||
| PH12015500985A1 (en) | Tec family kinase inhibitor adjuvant therapy | |
| SMT201700182T1 (it) | Composizioni di composti modificanti la risposta immunitaria lipidati, formulazioni e metodi | |
| EA201291157A1 (ru) | Мультивалентные вакцины с синтетическими наноносителями | |
| GB2518813A (en) | OMV vaccine against Burkholderia infections | |
| WO2011139348A3 (en) | Uses of phospholipid conjugates of synthetic tlr7 agonists | |
| UY34582A (es) | Anticuerpos anti-cxcr3 | |
| NZ603527A (en) | Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules | |
| UY34409A (es) | Inmunoenlazadores dirigidos contra el tnf | |
| IN2014DN08812A (enExample) | ||
| MX344009B (es) | Conjugados de amatoxinas con enlaces mejorados. | |
| EA201300585A1 (ru) | Иммуномодулирующие олигонуклеотиды | |
| ZA201309386B (en) | Vaccine composition comprising an inactivated chikungunya virus strain | |
| EP2764102A4 (en) | METHOD AND COMPOSITIONS FOR REGULATING HIV INFECTIONS | |
| NZ715459A (en) | A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same | |
| SG10201602424RA (en) | Antigen Presenting Cancer Vaccine With Gamma Interferon | |
| WO2013033496A3 (en) | Laser adjuvants for enhancing immune response | |
| EP2934578A4 (en) | VACCINES FOR CANCER TREATMENT AND COMPOSITIONS FOR INCREASING VACCINE EFFICACY | |
| HK1202070A1 (zh) | 用於肿瘤免疫疗法的疫苗 | |
| UY34286A (es) | Diagnóstico de vacuna mejorado | |
| HK1204962A1 (en) | Cyclodextrin-based polymers for therapeutic delivery | |
| EP2745844A4 (en) | MOLECULAR MIMETIC MUCOSAL VACCINE AGAINST AIDS |